Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07796373 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor
Secondary endpoints: details revised at 3 of 3 entries
Study description expanded, about 18 words
MinorStart date: Oct 13, 2026 to Oct 14, 2026v28
MinorStart date: Oct 12, 2026 to Oct 13, 2026v27
Show 25 earlier versionsHide 25 earlier versions
MinorStart date: Oct 11, 2026 to Oct 12, 2026v26
MinorStart date: Oct 8, 2026 to Oct 11, 2026v25
MinorStart date: Oct 7, 2026 to Oct 8, 2026v24
MinorStart date: Oct 6, 2026 to Oct 7, 2026v23
MinorStart date: Oct 5, 2026 to Oct 6, 2026v22
MinorStart date: Oct 4, 2026 to Oct 5, 2026v21
MinorStart date: Oct 1, 2026 to Oct 4, 2026v20
MinorStart date: Sep 30, 2026 to Oct 1, 2026v19
MinorStart date: Sep 29, 2026 to Sep 30, 2026v18
MinorStart date: Sep 28, 2026 to Sep 29, 2026v17
MinorStart date: Sep 27, 2026 to Sep 28, 2026v16
MinorStart date: Sep 24, 2026 to Sep 27, 2026v15
MinorStart date: Sep 23, 2026 to Sep 24, 2026v14
MinorStart date: Sep 22, 2026 to Sep 23, 2026v13
MinorStart date: Sep 21, 2026 to Sep 22, 2026v12
MinorStart date: Sep 20, 2026 to Sep 21, 2026v11
MinorStart date: Sep 17, 2026 to Sep 20, 2026v10
MinorStart date: Sep 16, 2026 to Sep 17, 2026v9
MinorStart date: Sep 15, 2026 to Sep 16, 2026v8
MinorStart date: Sep 14, 2026 to Sep 15, 2026
Study description revised
v7
MinorStart date: Sep 10, 2026 to Sep 14, 2026v6
MinorStart date: Sep 9, 2026 to Sep 10, 2026v5
MinorStart date: Sep 8, 2026 to Sep 9, 2026v4
MinorStart date: Sep 7, 2026 to Sep 8, 2026
Eligibility criteria shortened, about 8 words
v3
MinorStart date: Sep 6, 2026 to Sep 7, 2026v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background:
Chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) are diseases in which the body makes too many white blood cells that do not work properly. Because white cells play a role in immune function, people with CLL/SLL may be at greater risk of infections. CLL/SLL can be controlled with drugs, but many people develop resistance, and the treatments stop working.
Objective:
To test a new drug (nemtabrutinib) in people with CLL/SLL.
Eligibility:
People aged 18 years or older with CLL/SLL that persists despite treatment.
Design:
Participants will be screened. They will have imaging scans, blood and urine tests, and a test of their heart function. They will have a bone marrow biopsy: a sample of tissue and fluids will be drawn from inside their hip bone. They may also have a sample cut from a swollen lymph node, if one is safe to access.
Nemtabrutinib is a tablet taken by mouth. Participants will take the drug once a day at home in 4-week cycles. They will have clinic visits at least every 4 weeks for the first 6 months and then every 3 months after that.
Biopsies, imaging exams, and other tests may be repeated at these visits. Participants may also undergo lymphapheresis: Blood will be drawn from a tube inserted into a vein. The blood will pass through a machine that separates out cancer and immune cells. The remaining blood will be returned to the body through a different tube.
Participants may stay in the study as long as the drug is helping them.